Variable efficacy of N6-(1-iminoethyl)-L-lysine in acute cardiac transplant rejection

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 286, Issue 2 55-2, 2004, Pages

  Pieper, Galen M ^a   Nilakantan, Vani ^a   Hilton, Gail ^a   Zhou, Xianghua ^a   Khanna, Ashwani K ^a   Halligan, Nadine L N ^a   Felix, Christopher C ^a   Kampalath, Bal ^a   Griffith, Owen W ^a   Hayward, Mike A ^a   Roza, Allan M ^a   Adams, Mark B ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Activator protein 1; Electron paramagnetic resonance spectroscopy; Inducible nitric oxide synthase; Interferon ; Interleukin 10; Interleukin 6; Nuclear factor B

Indexed keywords

GAMMA INTERFERON; HEMOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; N6 (1 IMINOETHYL)LYSINE; NITRIC OXIDE SYNTHASE; TRANSCRIPTION FACTOR AP 1; DRUG DERIVATIVE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSINE; N(6) (1 IMINOETHYL)LYSINE; N(6)-(1-IMINOETHYL)LYSINE; NOS2 PROTEIN, RAT;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CELL INFILTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; ELECTRON SPIN RESONANCE; ENZYME INHIBITION; GENE EXPRESSION; GRAFT SURVIVAL; HEART GRAFT; IMMUNE RESPONSE; INFLAMMATORY CELL; NITROSYLATION; NONHUMAN; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN MODIFICATION; RAT; ALLOTRANSPLANTATION; ANIMAL; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; GRAFT REJECTION; HEART TRANSPLANTATION; IMMUNOLOGY; METABOLISM; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; DISEASE MODELS, ANIMAL; ELECTRON SPIN RESONANCE SPECTROSCOPY; ENZYME INHIBITORS; GRAFT REJECTION; HEART TRANSPLANTATION; HEMEPROTEINS; LYSINE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; RATS; RATS, SPRAGUE-DAWLEY; TIME FACTORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 19244374793     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.00356.2003     Document Type: Article

References (55)

1. Allione A, Bernabie P, Bosticardo M, Ariotti S, Forni G, and Novelli F. Nitric oxide suppresses human T lymphocyte proliferationas through IFNγ-dependent and IFNγ-independent induction of apoptosis. J Immunol 163: 4182-4191, 1999.
2. ω-monomethyl-L-arginine inhibits nitric oxide production in murine cardiac allografts but does not affect graft rejection. Biochim Biophys Acta 1226: 225-231, 1994.
3. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 11: 66-75, 2001.
4. 6-(iminoethyl)lysine. Biochemistry 37: 4844-4852, 1998.
5. Chen F, Kuhn DC, Sun SC, Gaydos LJ, and Demers LM. Dependence and reversal of nitric oxide production on NF-κB activation in silica and lipopolysaccharide-induced macrophages. Biochem Biophys Res Commun 214: 839-846, 1995.
6. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, and Currie WM. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 273: 15-24, 1995.
7. Cooper M, Lindholm P, Pieper G, Seibel R, Moore G, Nakanishi A, Dembny K, Komorowski R, Johnson C, Adams M, and Roza A. Myocardial nuclear factor-κB activity and nitric oxide production in rejecting cardiac allografts. Transplantation 66: 838-844, 1998.
8. Fuseler JW, Roerig SC, Grisham MB, Hall V, Jourd'heil S, Laroux S, and Wolf RE. Inhibition of inducible nitric oxide synthase exacerbates established joint inflammation and increases interleukin-6 levels in synovial tissue and serum (Abstract). Arthrit Rheum 41, Suppl: S99, 1998.
9. Kozlov AV, Sobhian B, Duvigneau C, Gemeiner M, Nohl H, Redl H, and Bahrami S. Organ specific formation of nitrosyl complexes under intestinal ischemia/reperfusion in rats involves NOS-independent mechanism(s). Shock 15: 366-371, 2001.
10. Kang JL, Lee K, and Castranova V. Nitric oxide up-regulates DNA-binding activity of nuclear factor-κB in macrophages stimulated with silica and inflammatory stimulants. Mol Cell Biochem 215: 1-9, 2000.
11. Koglin J, Granville DJ, Glysing-Jensen T, Mudgett JS, Carthy CM, McManus BM, and Russell ME. Attenuated acute cardiac rejection in NOS2-/- recipients correlates with reduced apoptosis. Circulation 99: 836-842, 1999.
12. Lander HM, Sehajpal PK, Levine DM, and Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 150: 1509-1516, 1993.
13. Langrehr JM, White DA, Hoffman RA, and Simmons RL. Macrophage produces nitric oxide at allograft sites. Ann Surg 218: 159-166, 1993.
14. Lewis NP, Tsao PS, Rickenbacher PR, Xue C, Johns RA, Haywood GA, von der Leyen H, Trindale PT, Cooke JP, Hunt SA, Billingham ME, Valantine HA, and Fowler MB. Induction of nitric oxide synthase in the human cardiac allograft is associated with contractile dysfunction of the left ventricle. Circulation 93: 720-729, 1996.
15. Li H, Samouilov A, Liu X, and Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrite reduction. Evaluation of its role in nitric oxide generation in anoxic tissues. J Biol Chem 276: 24482-24489, 2001.
16. Li H, Samoiulov A, Liu X, and Zweier JL. Characterization of the magnitude and kinetics of xanthine oxidase-catalyzed nitrate reduction: evaluation of its role in nitrite and nitric oxide generation in anoxic tissues. Biochemistry 42: 1150-1159, 2003.
17. Mannon RB, Roberts K, Ruiz P, Laubach V, and Coffman TM. Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection. J Heart Lung Transplant 18: 819-827, 1999.
18. Marks-Konczalik J, Chu SC, and Moss J. Cytokine-induced transcriptional induction of the human inducible nitric oxide synthase gene requires activator protein 1 and nuclear factor Kβ-binding sites. J Biol Chem 273: 22201-22208, 1998.
19. Matthews JR, Botting CH, Panico M, Morris HR, and Hay RT. Inhibition of NF-κB DNA binding by nitric oxide. Nucleic Acids Res 24: 2236-2242, 1996.
20. Mendes AF, Carvalho AP, Caramona MM, and Lopes MC. Role of nitric oxide in the activation of NF-κB, AP-1 and NOS II expression in articular chrondrocytes. Inflamm Res 51: 369-375, 2002.
21. 6-(1-iminoethyl)lysine: a selective inhibitor of inducible nitric oxide synthase. J Med Chem 37: 3886-3888, 1994.
22. Niu XL, Xia Y, Hoshiai K, Tanaka K, Sawamura S, and Nakazawa H. Inducible nitric oxide synthase knockout mouse macrophages disclose prooxidant effect of interferon-γ on low-density lipoprotein oxidation. Nitric Oxide 4: 363-371, 2000.
23. Pance A, Chantome A, Reveneau S, Bentrari F, and Jeanin JF. A repressor in the proximal human inducible nitric oxide synthase promoter modulates transcriptional activation. FASEB J 16: 631-633, 2002.
24. Park SK, Lin HL, and Murphy S. Nitric oxide regulates nitric oxide synthase-2 gene expression by inhibiting NF-κB binding to DNA. Biochem J 322: 609-613, 1997.
25. Paul LC, Myllärniemi M, Muzaffar S, and Benediktsson H. Nitric oxide synthase inhibition is associated with decreased survival of cardiac allografts in the rat. Transplantation 62: 1193-1195, 1996.
26. Peng HB, Libby P, and Liao JK. Induction and stabilization of IκBα by nitric oxide mediates inhibition of NF-κB. J Biol Chem 270: 14214-14219, 1995.
27. Pieper GM, Cooper M, Johnson CP, Adams MB, Felix CC, and Roza AM. Reduction of myocardial nitrosyl complex formation by a nitric oxide scavenger prolongs cardiac allograft survival. J Cardiovasc Pharmacol 35: 114-120, 2000.
28. Pieper GM, Halligan NL, Hilton G, Konorev EA, Felix CC, Roza AM, Adams MB, and Griffith OW. Non-heme protein: a potential target of nitric oxide in acute cardiac allograft rejection. Proc Natl Acad Sci USA 18: 3125-3130, 2003.
29. Pieper GM, Khanna AK, and Roza AM. Prolonging organ allograft survival: potential role of nitric oxide scavengers. Biodrugs 16: 37-45, 2002.
30. Pieper GM, Nilakantan V, Hilton G, Halligan NLN, Felix CC, Kampalath B, Khanna AK, Roza AM, Johnson CP, and Adams MB. Mechanisms of the protective action of diethyldithiocarbamate-iron complex on acute cardiac allograft rejection. Am J Physiol Heart Circ Physiol 284: H1542-H1551, 2003.
31. Pieper GM, Roza AM, Adams MB, Hilton G, Johnson M, Felix CC, Kampalath B, Darkes M, Wanggui Y, Cameron B, and Fricker SP. A ruthenium (III) polyaminocarboxylate complex, a novel nitric oxide scavenger, enhances graft survival and decreases nitrosylated heme protein in models of acute and delayed cardiac transplant rejection. J Cardiovasc Pharmacol 39: 441-448, 2002.
32. Pilz RB, Suhasini M, Idriss S, Meinkoth JL, and Boss GR. Nitric oxide and cGMP analogs activate transcription from AP-1-responsive promoters in mammalian cells. FASEB J 9: 552-558, 1995.
33. Rangan GK, Wang Y, and Harris DCH. Pharmacologic modulators of nitric oxide exacerbate tubulointerstitial inflammation in proteinuric rats. J Am Soc Nephrol 12: 1696-1705, 2001.
34. Reilly CM, Farrelly LW, Viti D, Redmond ST, Hutchison F, Ruiz P, Manning P, Connor J, and Gilkeson GS. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int 61: 839-846, 2002.
35. Roza AM, Cooper M, Pieper G, Hilton G, Dembny K, Lai CS, Lindholm P, Komorowski R, Felix C, Johnson C, and Adams M. NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Transplantation 69: 227-231, 2000.
36. Roza AM, Khanna AK, Pieper GM, Olds C, Baz R, Hilton G, and Adams M. Effects of antioxidant therapy on alloimmune activation and NF-κ B-dependent inflammatory cytokine gene expression (Abstract). Am J Transplant 1, Suppl 1: 268, 2001.
37. Salvemini D, Manning PT, Zweifel BS, Seibert K, Connor J, Currie MG, Needleman P, and Masferrer JL. Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J Clin Invest 96: 301-308, 1995.
38. Schuler W. Zur Hemmung der Diaminooxydase (Histaminase). Experientia 8: 230-232, 1952.
39. Shears LL II, Kawaharada N, Tzeng E, Billiar TB, Watkins SC, Kovesdi I, Lizonova A, and Pham SM. Inducible nitric oxide synthase suppresses the development of allograft arteriosclerosis. J Clin Invest 100: 2035-2042, 1997.
40. Soto PF, Jia CX, Rabkin DG, Hart JP, Carter YM, Sardo MJ, Hsu DT, Fisher PE, Pinsky DJ, and Spotnitz HM. Improvement of rejection-induced diastolic abnormalities in rat cardiac allografts with inducible nitric oxide synthase inhibition. J Thorac Cardiovasc Surg 120: 39-46, 2000.
41. G-monomethyl-arginine in vitro and in vivo. Eur J Pharmacol 294: 703-712, 1995.
42. +/+ mice. Effects of cellular chimeras on myocardial inflammation and cardiomyocyte damage and apoptosis. Circulation 103: 2514-2520, 2001.
43. Szabolcs MJ, Ravalli S, Minanov O, Sciacca RR, Michler RE, and Cannon PJ. Apoptosis and increased expression of inducible nitric oxide synthase in human allograft rejection. Transplantation 65: 804-812, 1998.
44. Szabolcs MJ, Sun J, Ma N, Albala A, Sciacca RR, Philips GB, Parkinson J, Edwards N, and Cannon PJ. Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation 106: 2392-2396, 2002.
45. Tabuchi A, Oh E, Taoka A, Sakurai H, Tsuchiya T, and Tsuda M. Rapid attentuation of AP-1 transcriptional factors associated with nitric oxide (NO)-mediated neuronal cell death. J Biol Chem 271: 31061-31067, 1996.
46. Tabuchi A, Sano K, Oh E, Tsuchiya T, and Tsuda M. Modulation of AP-1 activity by nitric oxide (NO) in vitro: NO-mediated modulation of AP-1. FEBS Lett 351: 123-127, 1994.
47. Takahishi W, Suzuki J, Izawa A, Takayama K, Yamazaki S, and Isobe M. Inducible nitric oxide-mediated myocardial apoptosis contributes to graft failure during acute cardiac allograft rejection in mice. Jap Heart J 41: 493-506, 2000.
48. Von Knethen A, Callsen D, and Brüne B. NF-κB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages. Mol Biol Cell 10: 361-372, 1999.
49. Winlaw DS, Schyvens CG, Smythe GA, Du ZY, Rainer SP, Lord RSA, Spratt PM, and Macdonald PS. Selective inhibition of nitric oxide production during cardiac allograft rejection causes a small increase in graft survival. Transplantation 60: 77-82, 1995.
50. Worrall NK, Chang K, Suau GM, Allison WS, Misko TP, Sullivan PM, Tilton RG, Williamson JR, and Ferguson TB Jr. Inhibition of inducible nitric oxide synthase prevents myocardial and systemic vascular barrier dysfunction during early cardiac allograft rejection. Circ Res 78: 769-779, 1996.
51. Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, Tilton RG, Williamson JR, and Ferguson TB Jr. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. J Exp Med 181: 63-70, 1995.
52. Worrall NK, Misko TP, Sullivan PM, Hui JJ, and Ferguson TB Jr. Inhibition of inducible nitric oxide synthase attenuates established acute cardiac allograft rejection. Ann Thorac Surg 62: 378-385, 1996.
53. Worrall NK, Pyo RT, Botney MD, Misko TP, Sullivan PM, Alexander DG, Lazenby WD, and Ferguson TB. Inflammatory cell-derived NO modulates cardiac allograft contractile and electrophysiological function. Am J Physiol Heart Circ Physiol 273: H28-H37, 1997.
54. Yang X, Chowdhury N, Cai B, Brett J, Marboe C, Sciacca RR, Michler RE, and Cannon PJ. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 94: 714-721, 1994.
55. Yang X, Ma N, Szabolcs MJ, Zhong J, Athan E, Sciacca RR, Michler RE, Anderson GD, Wiese JF, Leahy KM, Gregory S, and Cannon PJ. Upregulation of COX-2 during cardiac allograft rejection. Circulation 101: 430-438, 2000.